Skip to content

A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity

A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01477736
Enrollment
68
Registered
2011-11-22
Start date
2009-01-31
Completion date
2010-11-30
Last updated
2011-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injury

Keywords

Neurogenic bladder, Urodynamic, Quality of life

Brief summary

The purpose of this study is to compare the effects of oral oxybutynin and intradetrusor injections of botulinum toxin type A on urodynamic parameters and quality of life in patients with neurogenic detrusor overactivity following spinal cord injury.

Interventions

DRUGOxybutynin

5 mg of immediate-release oxybutynin orally 3 times daily

DRUGBotulinum toxin A

300 U intradetrusor injection

Sponsors

Centro de Reabilitação e Readaptação Dr. Henrique Santillo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Spinal cord injury * Detrusor overactivity * Age over 18 years * Spinal cord injury at least 12 months duration * Undergoing regular clean intermittent catheterisation

Exclusion criteria

* Pregnancy * Desire to become pregnant during the study period * Breastfeeding * Blood coagulation disorder * Neuromuscular transmission disorder * Use of any intravesical pharmacologic agents * Previous use of botulinum toxin A

Design outcomes

Primary

MeasureTime frame
The primary study outcome measure was the variation mean in the number of episodes of urinary incontinence per 24 hours, maximum cystometric capacity, maximum detrusor pressure and bladder complianceBeginning and 24 weeks of the study

Secondary

MeasureTime frame
The secondary outcome measure was quality of life as measured by the Qualiveen questionnaireBeginning and 24 weeks of the study

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026